Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Apr 3, 2018 (9 years ago)

Temozolomide 20 mg NDC 43975-0253-05 28 days supply

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Processing Controls.

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Temozolomide 20 mg NDC 43975-0253-05 28 days supply

Affected NDC 43975-0253-05

Compare with the code on your package — it is the most precise check available.

Drug: Temozolomide

Recalling firm
Kroger Specialty Pharmacy, Inc.
NDC code
43975-0253-05
Origin
MS, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0780-2018 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Temozolomide recalls

See all
Class II · Moderate risk

Product label: Temozolomide Capsules

Failed Impurities/Degradation Specifications: An out-of-specification result observed during 9th-month long term stability testing

Ongoing Impurity / degradation Rising Pharma Holding, Inc. NDC 16571-816-51 D-0384-2026
Class II · Moderate risk

Temozolomide Capsules

CGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.

Terminated Cross-contamination Deva Holding AS - Cerkezkoy Subesi NDC 67877-542-07 D-1513-2019
Class II · Moderate risk

Temozolomide Capsules

CGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.

Terminated Cross-contamination Deva Holding AS - Cerkezkoy Subesi NDC 67877-541-07 D-1512-2019
Class II · Moderate risk

Temozolomide Capsules

CGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.

Terminated Cross-contamination Deva Holding AS - Cerkezkoy Subesi NDC 67877-540-07 D-1511-2019
Class II · Moderate risk

Temozolomide Capsules

CGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.

Terminated Cross-contamination Deva Holding AS - Cerkezkoy Subesi NDC 67877-539-07 D-1510-2019

Other recalls by Kroger Specialty Pharmacy, Inc.

All 2018 recalls